Assessment of the HER2DX Assay in Patients With ERBB2-Positive Breast Cancer Treated With Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab.
Sign Up to like & getrecommendations! Published in 2023 at "JAMA oncology"
DOI: 10.1001/jamaoncol.2023.0181
Abstract: Importance Patients with early-stage ERBB2 (formerly HER2)-positive breast cancer (ERBB2+ BC) who experience a pathologic complete response (pCR) after receiving neoadjuvant therapy have favorable survival outcomes. Predicting the likelihood of pCR may help optimize neoadjuvant… read more here.
Keywords: her2dx assay; her2dx pcr; pcr score; pcr ... See more keywords